Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) — Net Asset Momentum
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) recorded a net asset momentum of -8.2% as of December 2025, with net assets of CN¥2.12 Billion CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Check how tangible is Shanghai Fudan-Zhangjiang Bio-Pharmaceut's equity to evaluate the tangible quality of the company's equity base.
YoY Momentum
Current Net Assets
Years of Data
Country
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Net Asset Momentum (2005–2025)
This chart tracks Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's year-over-year net asset growth across 21 annual reporting periods from 2005 to 2025. The most recent momentum reading is -8.2%, with net assets of CN¥2.12 Billion CNY as of December 2025. Read 688505 current and long-term liabilities for a breakdown of total debt and financial obligations.
Annual Net Asset History for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
The table below shows the complete annual net asset history for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025, covering 21 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see Shanghai Fudan-Zhangjiang Bio-Pharmaceut market cap and net worth.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | CN¥2.12 Billion | CN¥2.39 Billion | CN¥273.93 Million | ▼ -8.2% |
| 2024 | CN¥2.31 Billion | CN¥2.59 Billion | CN¥281.23 Million | ▼ -2.3% |
| 2023 | CN¥2.36 Billion | CN¥2.88 Billion | CN¥518.12 Million | ▲ +4.7% |
| 2022 | CN¥2.25 Billion | CN¥2.98 Billion | CN¥722.99 Million | ▲ +2.9% |
| 2021 | CN¥2.19 Billion | CN¥2.78 Billion | CN¥591.58 Million | ▲ +9.0% |
| 2020 | CN¥2.01 Billion | CN¥2.50 Billion | CN¥492.21 Million | ▲ +115.2% |
| 2019 | CN¥933.15 Million | CN¥1.56 Billion | CN¥631.68 Million | ▼ -6.1% |
| 2018 | CN¥993.28 Million | CN¥1.46 Billion | CN¥466.08 Million | ▲ +11.3% |
| 2017 | CN¥892.48 Million | CN¥1.15 Billion | CN¥252.65 Million | ▲ +2.2% |
| 2016 | CN¥873.05 Million | CN¥1.12 Billion | CN¥247.70 Million | ▲ +14.0% |
| 2015 | CN¥765.84 Million | CN¥1.02 Billion | CN¥254.43 Million | ▲ +13.2% |
| 2014 | CN¥676.42 Million | CN¥824.48 Million | CN¥148.06 Million | ▲ +19.5% |
| 2013 | CN¥565.92 Million | CN¥749.22 Million | CN¥183.29 Million | ▲ +117.6% |
| 2012 | CN¥260.11 Million | CN¥537.30 Million | CN¥277.18 Million | ▲ +29.4% |
| 2011 | CN¥201.07 Million | CN¥358.88 Million | CN¥157.81 Million | ▲ +19.2% |
| 2010 | CN¥168.71 Million | CN¥304.15 Million | CN¥135.45 Million | ▲ +0.2% |
| 2009 | CN¥168.37 Million | CN¥298.83 Million | CN¥130.46 Million | ▲ +121.9% |
| 2008 | CN¥75.88 Million | CN¥158.45 Million | CN¥82.57 Million | ▲ +6.8% |
| 2007 | CN¥71.04 Million | CN¥130.38 Million | CN¥59.34 Million | ▼ -30.1% |
| 2006 | CN¥101.70 Million | CN¥145.02 Million | CN¥43.32 Million | ▼ -17.8% |
| 2005 | CN¥123.73 Million | CN¥142.91 Million | CN¥19.18 Million | — |